O
TVTX icon

OrbiMed’s Travere Therapeutics TVTX Stock Holding History

OrbiMed’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,118,100
Closed -$32.5M – 145
2023
Q2 		$32.5M Buy
2,118,100
+373,800
+21% +$6.8M 0.59% 56
2023
Q1 		$39.2M Buy
1,744,300
+491,170
+39% +$10.4M 0.78% 43
2022
Q4 		$26.4M Hold
1,253,130
– – 0.5% 59
2022
Q3 		$30.9K Buy
1,253,130
+480,930
+62% +$12.4M 0.57% 57
2022
Q2 		$18.7K Buy
+772,200
New +$19.4M 0.34% 65
2021
Q2 		– Sell
-528,100
Closed -$13.2M – 180
2021
Q1 		$13.2M Buy
+528,100
New +$14.6M 0.12% 112

Other funds holding TVTX

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $3.03B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $4.85B AUM 144% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return